- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07942792
Evaluation of Unexplained Severe Syncope in a Modern Syncope Unit (Diamond)
Evidence-based Evaluation of Unexplained Severe Syncope in a Modern Syncope Unit: an Observational Study
The aim of the present study is to evaluate clinical practice in the diagnosis of severe unexplained syncope among European Syncope Units adhering to the standards set forth by the ESC guidelines.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The Diamond study is an investigator-initiated, prospective, international, multicenter study, coordinated by the non-profit organization Gruppo Italiano Studio Sincope (GIMSI), conducted within European Syncope Units that fulfill the personnel and equipment criteria recommended by the European Heart Rhythm Association (EHRA) and the (GIMSI) (https://www.gimsi.it/modello-organizzativo/).
Eligibility of each center is certified by the head of the syncope unit, who completes a questionnaire confirming compliance with the required standards. Web-based Clinical Report Form (CRF). To allow uniform clinical data collection from participating centres, a web-based CRF, was designed Study workflow. Following documented patient consent, clinical personnel at the site -trained in the use of the web-app- will access the digital tool to enter the patient's I/E criteria assessment, personal information and medical history. From that point forward, data will be entered into the web-app on an ongoing basis, in accordance with the site's routine clinical practice, until the patient reaches a defined exit point (such as diagnosis of cardiac syncope, diagnosis of autonomic syncope, no syncope, no diagnosis), or drop-out (e.g., patient death, patient unable to comply with diagnostic pathway, etc.).
Tipo di studio
Iscrizione (Stimato)
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Consecutive patients referred to the Syncope Unit for severe unexplained syncope
Descrizione
Inclusion Criteria: Outpatients aged ≥16 years referred to the Syncope Unit due to severe, unexplained syncope and/or unexplained fall requiring comprehensive evaluation to identify the most appropriate mechanism-specific therapy.
Exclusion Criteria: Non-severe syncope Definitions.
-
Unexplained syncope is defined as unexplained etiology or unexplained
-
Severe syncope is defined by the presence of one or more among the following:
-
Suspected life-threatening arrhythmias
-
Substantial impact on patient's quality of life (QoL)
- Frequent episodes
- Restriction of educational or occupational activities (including, but not limited to, unemployment)
- Restriction of social or daily-life activities, e.g. when syncope occurs while driving
-
High risk of clinically significant outcomes
- Syncope associated with major injuries/trauma, i.e. head injury or fractures
- Unpredictable syncope, i.e. without prodrome or identifiable triggers
-
Presence of serious comorbidities, such as concomitant heart disease, neurologic disease, diabetes or renal failure
-
Suspected Autonomic syncope overlapping with suspected psychogenic pseudosyncope
-
-
Non-severe syncope is defined by the presence of one or more among the following:
- Sporadic (isolated) episodes without major impact on patient's QoL
- Predictable syncope, i.e. syncope preceded by prodrome and/or occurring in association with identifiable triggers, with low risk of injuries
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Unexplained syncope
Syncope Unit |
At the initial evaluation, it is essential to exclude non-syncopal causes of transient loss of consciousness (TLOC) - such as epilepsy, psychogenic pseudosyncope, and other conditions of apparent loss of consciousness that may be incorrectly diagnosed as syncope. Once non-syncopal causes have been excluded and the loss of consciousness is determined to be syncopal in nature, the primary objective of the diagnostic work-up is to identify cases of cardiac syncope. Cardiac syncope is characterized by loss of consciousness due to a primary cardiac disorder, such as arrhythmias or structural heart disease, and requires prompt recognition and appropriate treatment due to its association with higher morbidity and mortality. When both cardiac syncope and non-syncopal causes of TLOC are reasonably ruled out, the diagnosis of autonomic syncope becomes likely. Autonomic syncope encompasses both reflex (neurally mediated) syncope and orthostatic hypotension and represents the most frequent cause |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Rate of final diagnoses 2) Type of final diagnoses 3) Number of tests utilized to reach them.
Lasso di tempo: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Number of participants with adherence of the clinical practices to a theoretical diagnostic pathway
Lasso di tempo: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
|
Assessment of number and costs of resource utilization associated to the clinical practices
Lasso di tempo: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
Collaboratori e investigatori
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 09X605
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .